Volume 13, Issue 3 (Vol.13 No.3 Oct 2024)                   rbmb.net 2024, 13(3): 341-348 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Burhan Altemimi R, Nabil Ibrahim N, Ali Nazar L, Ali Hasan H, Heilo Al-Musawi M, Mortazavi Moghadam F. The Predictive Value of Melatonin Levels for the Development of Diabetic Nephropathy in Men with Type 2 Diabetes Mellitus. rbmb.net 2024; 13 (3) :341-348
URL: http://rbmb.net/article-1-1371-en.html
Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
Abstract:   (524 Views)
Background: Type 2 diabetes mellitus (T2DM) poses a significant public health challenge due to its high prevalence. Diabetic nephropathy (DN) is one of the most severe complications associated with T2DM. Early prediction of DN in patients with T2DM can significantly aid in managing this disease. This study takes an approach by investigating the potential role of melatonin and thyroid hormone levels as predictive biomarkers for the progression of diabetic nephropathy in individuals diagnosed with type 2 diabetes mellitus.

Methods: Our cross-sectional study involved 120 male participants, divided into two groups: 60 patients with T2DM and 60 with DN. The Cobas technique was used to measure serum thyroid hormone levels and quantified melatonin levels using an enzyme-linked immunosorbent assay (ELISA). A receiver utilizing characteristic (ROC) curve analysis to evaluate the predictive value of serum melatonin for DN was performed.

Results: No notable disparities in thyroid function tests were observed between diabetic patients with and without DN. However, the average serum melatonin quantity in patients with DN. (177.25 ± 60.48 pg/mL) was drastically lower in those with T2DM without DN (199.9 ± 55.16 pg/mL). The sensitivity and specificity of melatonin in predicting DN were 78% and 76%, respectively, with an optimal cut-off value of 178 pg/mL.

Conclusions: Serum melatonin levels exhibited a notable reduction. among individuals who were diabetic with DN, suggesting its potential utility as an additional predictive marker for developing DN in patients with T2DM.
Full-Text [PDF 340 kb]   (149 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2024/04/14 | Accepted: 2024/07/14 | Published: 2025/04/12

References
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1(Suppl 1):S62-9. [DOI:10.2337/dc10-S062] [PMID] []
2. Roglic, G. WHO Global report on diabetes: A summary. Int J Noncommunicable Dis. 2016;1(1):3-8. [DOI:10.4103/2468-8827.184853]
3. Derakhshanian H, Djazayery A, Javanbakht MH, Eshraghian MR, Mirshafiey A, Zarei M, et al. The Effect of Vitamin D on Cellular Pathways of Diabetic Nephropathy. Rep Biochem Mol Biol. 2019 ;7(2):217-222.
4. Wang G, Ouyang J, Li S, Wang H, Lian B, Liu Z, Xie L. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. J Transl Med. 2019;17(1):264. [DOI:10.1186/s12967-019-2016-y] [PMID] []
5. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813-21. [DOI:10.1681/ASN.2008121270] [PMID] []
6. Jung KH, Hong SW, Zheng HM, Lee HS, Lee H, Lee DH, et al. Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res. 2010;48(3):239-250. [DOI:10.1111/j.1600-079X.2010.00748.x] [PMID]
7. Zephy D, Ahmad J. Type 2 diabetes mellitus: Role of melatonin and oxidative stress. Diabetes Metab Syndr. 2015;9(2):127-31. [DOI:10.1016/j.dsx.2014.09.018] [PMID]
8. Han C, Xia X, Liu A, Zhang X, Zhou M, Xiong C, et al. Circulating Betatrophin Is Increased in Patients with Overt and Subclinical Hypothyroidism. Biomed Res Int. 2016;2016:5090852. [DOI:10.1155/2016/5090852] [PMID] []
9. Han C, Rice MW, Cai D. Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am J Physiol Endocrinol Metab. 2016;311(1):E32-41. [DOI:10.1152/ajpendo.00012.2016] [PMID] []
10. Zhang Y, Chang Y, Ryu S, Cho J, Lee WY, Rhee EJ, et al. Thyroid hormone levels and incident chronic kidney disease in euthyroid individuals: the Kangbuk Samsung Health Study. Int J Epidemiol. 2014;43(5):1624-32. [DOI:10.1093/ije/dyu126] [PMID]
11. Javanbakht MH, Mohammady H, Fooladsaz K, Razzaghi M, Zarei M, Djalali M. Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study. Rep Biochem Mol Biol. 2016;5(1):26-32.
12. Wu J, Li X, Tao Y, Wang Y, Peng Y. Free Triiodothyronine Levels Are Associated with Diabetic Nephropathy in Euthyroid Patients with Type 2 Diabetes. Int J Endocrinol. 2015;2015:204893. [DOI:10.1155/2015/204893] [PMID] []
13. Zhao W, Li X, Liu X, Lu L, Gao Z. Thyroid Function in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy: A Single Center Study. J Thyroid Res. 2018;2018:9507028. [DOI:10.1155/2018/9507028] [PMID] []
14. Liu MC, Li JL, Wang YF, Meng Y, Cai Z, Shen C, Wang MD, Zhao WJ, Niu WQ. Association between thyroid hormones and diabetic kidney disease in Chinese adults. BMC Endocr Disord. 2023;23(1):56. https://doi.org/10.1186/s12902-021-00717-6 [DOI:10.1186/s12902-023-01299-1]
15. Han C, He X, Xia X, Li Y, Shi X, Shan Z, Teng W. Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(8):e0135233. [DOI:10.1371/journal.pone.0135233] [PMID] []
16. Iglesias P, Bajo MA, Selgas R, Díez JJ. Thyroid dysfunction and kidney disease: An update. Rev Endocr Metab Disord. 2017 Mar;18(1):131-144. [DOI:10.1007/s11154-016-9395-7] [PMID]
17. Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol. 2012;23(1):22-6. [DOI:10.1681/ASN.2010070766] [PMID]
18. McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. JAMA. 2013;309(13):1388-96. [DOI:10.1001/jama.2013.2710] [PMID] []
19. Motawi TK, Ahmed SA, Hamed MA, El-Maraghy SA, Aziz WM. Combination of melatonin and certain drugs for treatment of diabetic nephropathy in streptozotocin-induced diabetes in rats. Diabetol Int. 2016;7(4):413-424. [DOI:10.1007/s13340-016-0268-9] [PMID] []
20. Liu F, Zhang S, Xu R, Gao S, Yin J. Melatonin Attenuates Endothelial-to-Mesenchymal Transition of Glomerular Endothelial Cells via Regulating miR-497/ROCK in Diabetic Nephropathy. Kidney Blood Press Res. 2018;43(5):1425-1436. [DOI:10.1159/000493380] [PMID]
21. Onk D, Onk OA, Turkmen K, Erol HS, Ayazoglu TA, Keles ON, et al. Melatonin Attenuates Contrast-Induced Nephropathy in Diabetic Rats: The Role of Interleukin-33 and Oxidative Stress. Mediators Inflamm. 2016;2016:9050828. [DOI:10.1155/2016/9050828] [PMID] []
22. Sailaja Devi MM, Suresh Y, Das. Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin. J Pineal Res. 2000;29(2):108-15. [DOI:10.1034/j.1600-079X.2000.290207.x] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb